APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

NK Cell Therapy

Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.

Selected research

Market Outlook & Growth Opportunities

Global NK Cell Therapy Market Outlook and Growth Opportunities 2026

Report ID 173916700420 December 2025194 pages

Choose your research edition.

Industry ResearchNK Cell Therapy Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal NK Cell Therapy Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal NK Cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NK Cell Therapy Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal NK Cell Therapy Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.

North America is the largest NK Cell Therapy market with about 51% market share. Europe is follower, accounting for about 33% market share.The key manufacturers are Nektar Therapeutics, Innate Pharma SA, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem Therapeutics, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics, Fortress Biotech etc. Top 3 companies occupied about 82% market share.

This report provides an overview of the global NK Cell Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of NK Cell Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents NK Cell Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global NK Cell Therapy market.

NK Cell Therapy Segment by Company

Nektar Therapeutics

Innate Pharma SA

Affimed

Chipscreen Biosciences

Fate Therapeutics

Glycostem Therapeutics

Dragonfly Therapeutics

Kiadis Pharma

NantWorks

Nkarta Therapeutics

Fortress Biotech

NK Cell Therapy Segment by Type

NK Cell Therapies

NK Cell Directed Antibodies

NK Cell Therapy Segment by Application

Cancer

Gastrointestinal Diseases

Others

NK Cell Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global NK Cell Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the NK Cell Therapy key companies, revenue, market share, and recent developments.

3. To split the NK Cell Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions NK Cell Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify NK Cell Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze NK Cell Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NK Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK Cell Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global NK Cell Therapy industry.

Chapter 3: Detailed analysis of NK Cell Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of NK Cell Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of NK Cell Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. NK Cell Therapy Industry Trends Table 2. NK Cell Therapy Industry Drivers Table 3. NK Cell Therapy Industry Opportunities and Challenges Table 4. NK Cell Therapy Industry Restraints Table 5. Global NK Cell Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global NK Cell Therapy Revenue Share by Company (2021-2026) Table 7. Global NK Cell Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global NK Cell Therapy Key Company Manufacturing Base & Headquarters Table 9. Global NK Cell Therapy Company, Product Type & Application Table 10. Global NK Cell Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global NK Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of NK Cell Therapies Table 15. Significant Companies of NK Cell Directed Antibodies Table 16. Global NK Cell Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global NK Cell Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global NK Cell Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global NK Cell Therapy Sales Value Share by Type (2021-2026) Table 20. Global NK Cell Therapy Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Cancer Table 22. Significant Companies of Gastrointestinal Diseases Table 23. Significant Companies of Others Table 24. Global NK Cell Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global NK Cell Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global NK Cell Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global NK Cell Therapy Sales Value Share by Application (2021-2026) Table 28. Global NK Cell Therapy Sales Value Share by Application (2027-2032) Table 29. Global NK Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global NK Cell Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global NK Cell Therapy Sales Value Share by Region (2021-2026) Table 32. Global NK Cell Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global NK Cell Therapy Sales Value Share by Region (2027-2032) Table 34. Global NK Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global NK Cell Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global NK Cell Therapy Sales Value Market Share by Country (2021-2026) Table 37. Global NK Cell Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global NK Cell Therapy Sales Value Market Share by Country (2027-2032) Table 39. Nektar Therapeutics Company Information Table 40. Nektar Therapeutics Business Overview Table 41. Nektar Therapeutics NK Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Nektar Therapeutics NK Cell Therapy Product Portfolio Table 43. Nektar Therapeutics Recent Development Table 44. Innate Pharma SA Company Information Table 45. Innate Pharma SA Business Overview Table 46. Innate Pharma SA NK Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Innate Pharma SA NK Cell Therapy Product Portfolio Table 48. Innate Pharma SA Recent Development Table 49. Affimed Company Information Table 50. Affimed Business Overview Table 51. Affimed NK Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Affimed NK Cell Therapy Product Portfolio Table 53. Affimed Recent Development Table 54. Chipscreen Biosciences Company Information Table 55. Chipscreen Biosciences Business Overview Table 56. Chipscreen Biosciences NK Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Chipscreen Biosciences NK Cell Therapy Product Portfolio Table 58. Chipscreen Biosciences Recent Development Table 59. Fate Therapeutics Company Information Table 60. Fate Therapeutics Business Overview Table 61. Fate Therapeutics NK Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Fate Therapeutics NK Cell Therapy Product Portfolio Table 63. Fate Therapeutics Recent Development Table 64. Glycostem Therapeutics Company Information Table 65. Glycostem Therapeutics Business Overview Table 66. Glycostem Therapeutics NK Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Glycostem Therapeutics NK Cell Therapy Product Portfolio Table 68. Glycostem Therapeutics Recent Development Table 69. Dragonfly Therapeutics Company Information Table 70. Dragonfly Therapeutics Business Overview Table 71. Dragonfly Therapeutics NK Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Dragonfly Therapeutics NK Cell Therapy Product Portfolio Table 73. Dragonfly Therapeutics Recent Development Table 74. Kiadis Pharma Company Information Table 75. Kiadis Pharma Business Overview Table 76. Kiadis Pharma NK Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Kiadis Pharma NK Cell Therapy Product Portfolio Table 78. Kiadis Pharma Recent Development Table 79. NantWorks Company Information Table 80. NantWorks Business Overview Table 81. NantWorks NK Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. NantWorks NK Cell Therapy Product Portfolio Table 83. NantWorks Recent Development Table 84. Nkarta Therapeutics Company Information Table 85. Nkarta Therapeutics Business Overview Table 86. Nkarta Therapeutics NK Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Nkarta Therapeutics NK Cell Therapy Product Portfolio Table 88. Nkarta Therapeutics Recent Development Table 89. Fortress Biotech Company Information Table 90. Fortress Biotech Business Overview Table 91. Fortress Biotech NK Cell Therapy Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 92. Fortress Biotech NK Cell Therapy Product Portfolio Table 93. Fortress Biotech Recent Development Table 94. Research Programs/Design for This Report Table 95. Authors List of This Report Table 96. Secondary Sources Table 97. Primary Sources List of Figures Figure 1. NK Cell Therapy Product Image Figure 2. Global NK Cell Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NK Cell Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global NK Cell Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. NK Cell Therapies Image Figure 8. NK Cell Directed Antibodies Image Figure 9. Global NK Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global NK Cell Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global NK Cell Therapy Sales Value Share by Type (2021-2032) Figure 12. Cancer Image Figure 13. Gastrointestinal Diseases Image Figure 14. Others Image Figure 15. Global NK Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global NK Cell Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global NK Cell Therapy Sales Value Share by Application (2021-2032) Figure 18. Global NK Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global NK Cell Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America NK Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 21. North America NK Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe NK Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 23. Europe NK Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific NK Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific NK Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America NK Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 27. South America NK Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa NK Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa NK Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt NK Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt NK Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt NK Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • NK Cell Therapies
  • NK Cell Directed Antibodies
Applications
  • Cancer
  • Gastrointestinal Diseases
  • Others
Companies covered
  • Nektar Therapeutics
  • Innate Pharma SA
  • Affimed
  • Chipscreen Biosciences
  • Fate Therapeutics
  • Glycostem Therapeutics
  • Dragonfly Therapeutics
  • Kiadis Pharma
  • NantWorks
  • Nkarta Therapeutics
  • Fortress Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global NK Cell Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global NK Cell Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 NK Cell Therapy Market Dynamics
  1. 2.1 NK Cell Therapy Industry Trends
  2. 2.2 NK Cell Therapy Industry Drivers
  3. 2.3 NK Cell Therapy Industry Opportunities and Challenges
  4. 2.4 NK Cell Therapy Industry Restraints
3 NK Cell Therapy Market by Company
  1. 3.1 Global NK Cell Therapy Company Revenue Ranking in 2025
  2. 3.2 Global NK Cell Therapy Revenue by Company (2021-2026)
  3. 3.3 Global NK Cell Therapy Company Ranking (2024-2026)
  4. 3.4 Global NK Cell Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global NK Cell Therapy Company Product Type and Application
  6. 3.6 Global NK Cell Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global NK Cell Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 NK Cell Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 NK Cell Therapy Market by Type
  1. 4.1 NK Cell Therapy Type Introduction
  2. 4.1.1 NK Cell Therapies
  3. 4.1.2 NK Cell Directed Antibodies
  4. 4.2 Global NK Cell Therapy Sales Value by Type
  5. 4.2.1 Global NK Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global NK Cell Therapy Sales Value by Type (2021-2032)
  7. 4.2.3 Global NK Cell Therapy Sales Value Share by Type (2021-2032)
5 NK Cell Therapy Market by Application
  1. 5.1 NK Cell Therapy Application Introduction
  2. 5.1.1 Cancer
  3. 5.1.2 Gastrointestinal Diseases
  4. 5.1.3 Others
  5. 5.2 Global NK Cell Therapy Sales Value by Application
  6. 5.2.1 Global NK Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global NK Cell Therapy Sales Value by Application (2021-2032)
  8. 5.2.3 Global NK Cell Therapy Sales Value Share by Application (2021-2032)
6 NK Cell Therapy Regional Value Analysis
  1. 6.1 Global NK Cell Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global NK Cell Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global NK Cell Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global NK Cell Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America NK Cell Therapy Sales Value (2021-2032)
  7. 6.3.2 North America NK Cell Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe NK Cell Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe NK Cell Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific NK Cell Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific NK Cell Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America NK Cell Therapy Sales Value (2021-2032)
  16. 6.6.2 South America NK Cell Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa NK Cell Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa NK Cell Therapy Sales Value Share by Country, 2025 VS 2032
7 NK Cell Therapy Country-level Value Analysis
  1. 7.1 Global NK Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global NK Cell Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global NK Cell Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global NK Cell Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA NK Cell Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada NK Cell Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico NK Cell Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany NK Cell Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France NK Cell Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. NK Cell Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy NK Cell Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain NK Cell Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia NK Cell Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands NK Cell Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries NK Cell Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China NK Cell Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan NK Cell Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea NK Cell Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India NK Cell Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia NK Cell Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia NK Cell Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil NK Cell Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina NK Cell Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile NK Cell Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia NK Cell Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru NK Cell Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia NK Cell Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel NK Cell Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE NK Cell Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey NK Cell Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran NK Cell Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt NK Cell Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt NK Cell Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt NK Cell Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Nektar Therapeutics
  2. 8.1.1 Nektar Therapeutics Company Information
  3. 8.1.2 Nektar Therapeutics Business Overview
  4. 8.1.3 Nektar Therapeutics NK Cell Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Nektar Therapeutics NK Cell Therapy Product Portfolio
  6. 8.1.5 Nektar Therapeutics Recent Developments
  7. 8.2 Innate Pharma SA
  8. 8.2.1 Innate Pharma SA Company Information
  9. 8.2.2 Innate Pharma SA Business Overview
  10. 8.2.3 Innate Pharma SA NK Cell Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Innate Pharma SA NK Cell Therapy Product Portfolio
  12. 8.2.5 Innate Pharma SA Recent Developments
  13. 8.3 Affimed
  14. 8.3.1 Affimed Company Information
  15. 8.3.2 Affimed Business Overview
  16. 8.3.3 Affimed NK Cell Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Affimed NK Cell Therapy Product Portfolio
  18. 8.3.5 Affimed Recent Developments
  19. 8.4 Chipscreen Biosciences
  20. 8.4.1 Chipscreen Biosciences Company Information
  21. 8.4.2 Chipscreen Biosciences Business Overview
  22. 8.4.3 Chipscreen Biosciences NK Cell Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Chipscreen Biosciences NK Cell Therapy Product Portfolio
  24. 8.4.5 Chipscreen Biosciences Recent Developments
  25. 8.5 Fate Therapeutics
  26. 8.5.1 Fate Therapeutics Company Information
  27. 8.5.2 Fate Therapeutics Business Overview
  28. 8.5.3 Fate Therapeutics NK Cell Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Fate Therapeutics NK Cell Therapy Product Portfolio
  30. 8.5.5 Fate Therapeutics Recent Developments
  31. 8.6 Glycostem Therapeutics
  32. 8.6.1 Glycostem Therapeutics Company Information
  33. 8.6.2 Glycostem Therapeutics Business Overview
  34. 8.6.3 Glycostem Therapeutics NK Cell Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Glycostem Therapeutics NK Cell Therapy Product Portfolio
  36. 8.6.5 Glycostem Therapeutics Recent Developments
  37. 8.7 Dragonfly Therapeutics
  38. 8.7.1 Dragonfly Therapeutics Company Information
  39. 8.7.2 Dragonfly Therapeutics Business Overview
  40. 8.7.3 Dragonfly Therapeutics NK Cell Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Dragonfly Therapeutics NK Cell Therapy Product Portfolio
  42. 8.7.5 Dragonfly Therapeutics Recent Developments
  43. 8.8 Kiadis Pharma
  44. 8.8.1 Kiadis Pharma Company Information
  45. 8.8.2 Kiadis Pharma Business Overview
  46. 8.8.3 Kiadis Pharma NK Cell Therapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kiadis Pharma NK Cell Therapy Product Portfolio
  48. 8.8.5 Kiadis Pharma Recent Developments
  49. 8.9 NantWorks
  50. 8.9.1 NantWorks Company Information
  51. 8.9.2 NantWorks Business Overview
  52. 8.9.3 NantWorks NK Cell Therapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 NantWorks NK Cell Therapy Product Portfolio
  54. 8.9.5 NantWorks Recent Developments
  55. 8.10 Nkarta Therapeutics
  56. 8.10.1 Nkarta Therapeutics Company Information
  57. 8.10.2 Nkarta Therapeutics Business Overview
  58. 8.10.3 Nkarta Therapeutics NK Cell Therapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Nkarta Therapeutics NK Cell Therapy Product Portfolio
  60. 8.10.5 Nkarta Therapeutics Recent Developments
  61. 8.11 Fortress Biotech
  62. 8.11.1 Fortress Biotech Company Information
  63. 8.11.2 Fortress Biotech Business Overview
  64. 8.11.3 Fortress Biotech NK Cell Therapy Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Fortress Biotech NK Cell Therapy Product Portfolio
  66. 8.11.5 Fortress Biotech Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst